Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
This page provides a historical news archive for iCAD, Inc. (formerly NASDAQ: ICAD), a company that described itself as a global leader in clinically proven AI-powered breast health and cancer detection solutions. Before becoming a wholly owned subsidiary of RadNet, Inc., iCAD regularly issued news releases detailing its product developments, clinical research, commercial partnerships, and financial performance.
Readers can review announcements about the ProFound Breast Health Suite, which iCAD characterized as an industry-leading AI-powered mammography analysis platform for breast cancer detection, density assessment, and risk evaluation. News items include updates on FDA clearances for ProFound Detection versions, the introduction of ProFound Cloud as a scalable SaaS platform, and collaborations that integrated iCAD’s AI technology into radiology information systems, PACS platforms, and cloud-based precision imaging networks.
The archive also covers financial news, such as quarterly and annual results, trends in annual recurring revenue associated with the company’s transition to a subscription and cloud-based model, and commentary from management on operating performance. Additional releases highlight clinical abstracts and presentations at major conferences, where research collaborators evaluated iCAD’s AI tools for early detection, risk prediction, and breast arterial calcification assessment across diverse populations.
Because iCAD completed a merger with RadNet in July 2025 and its common stock ceased trading independently, the ICAD news feed now serves as a record of historical communications from iCAD’s time as a standalone public company. Investors, clinicians, and researchers can use this archive to understand how the company described its technology, strategy, and clinical evidence prior to its integration into RadNet’s diagnostic imaging and digital health portfolio.
iCAD announced the release of its financial results for Q1 2021, scheduled for April 28, 2021, after market close. The company, a leader in medical technology for cancer detection and therapy, will host a conference call at 4:30 PM ET to discuss the results. Investors can join the call via domestic and international numbers or through a webcast link provided in the announcement.
This update is vital for stakeholders monitoring iCAD's performance in the medical technology sector.
iCAD has presented new research at two leading breast imaging conferences demonstrating the efficacy of ProFound AI in improving mammogram assessments. The findings indicate that ProFound AI accurately identifies 33.4% of normal cases without missing cancers, increasing to 58.6% when considering breast density and age. The AI tool enhances radiologists' sensitivity and specificity while reducing workload. Version 3.0 of ProFound AI, recently FDA-cleared, shows up to a 10% improvement in specificity and 1% in sensitivity compared to its predecessor, validating its clinical significance.
iCAD anticipates first-quarter 2021 revenues to exceed $8.1 million, reflecting significant growth compared to 2020. Key contributors include the successful market penetration of its ProFound AI products and Xoft Therapy. Cash equivalents stand at approximately $46.9 million, bolstered by a recent public offering of $25 million. Additionally, iCAD's CFO will depart in early May, prompting a search for a successor. While the preliminary results are promising, they are subject to change and may significantly differ from final consolidated financial statements.
iCAD announced a retrospective analysis published in the Journal of Medical Screening showing that its ProFound AI for 2D Mammography could detect 48% of interval cancers, including 93% of false negatives and minimal sign lesions. The study involved 37,367 women screened between 2011 and 2012, identifying various categories of interval cancers. This could enhance breast cancer detection rates in organized screening programs, ultimately leading to earlier treatment and improved outcomes for women.
iCAD announced FDA clearance for ProFound AI Version 3.0 for Digital Breast Tomosynthesis, enhancing algorithm specificity by 10% and processing speed by 40%. This third generation AI solution aids in the detection of malignant lesions, improving efficiency for radiologists. Developed using over 5 million images, this software aims to reduce false positives while maintaining cancer detection rates. The CEO highlighted the significance of these advancements in cancer detection, emphasizing the potential for improved clinical decision-making.
iCAD (NASDAQ: ICAD) showcased its expanded ProFound AI platform at the ECR 2021 Congress, featuring ProFound AI Risk, the first decision support tool providing short-term cancer risk estimations based on mammograms. New research indicated ProFound AI for Digital Breast Tomosynthesis (DBT) accurately identified 33.4% of screening exams as low-risk, with 0% false negatives. Additionally, ProFound AI Risk demonstrated superior performance in predicting individual cancer risk, enhancing clinicians' workflow and efficiency. iCAD continues to strengthen its position in innovative cancer detection solutions.
iCAD, Inc. (NASDAQ: ICAD) announced the successful closing of a public offering of 1,393,738 shares at $18.00 per share, raising gross proceeds of approximately $25.0 million as of March 5, 2021. The offering included the full exercise of an option by underwriters for an additional 171,516 shares. The funds will be used for working capital and general corporate purposes. Guggenheim Securities acted as the sole book-running manager. The securities were offered under effective registration statements with the SEC.
NASHUA, N.H., March 3, 2021 - iCAD, a leader in medical technology for cancer detection and therapy, announced that CEO Michael Klein will present at the Cowen 41st Annual Health Care Conference on March 4 at 12:10 PM ET. The presentation will include one-on-one investor meetings, with a live audio webcast available via iCAD’s investor website. iCAD's innovative products, including ProFound AI for mammography and the Xoft System for localized cancer treatment, are designed to improve efficiency and patient outcomes.
iCAD, Inc. (NASDAQ: ICAD) announced a public offering of 1,222,222 shares at $18.00 each, aiming for gross proceeds of approximately $22 million. The offering's closing is anticipated around March 5, 2021, pending customary conditions. Underwriters, led by Guggenheim Securities, have a 30-day option for an additional 171,516 shares. Proceeds will be used for working capital and corporate purposes. The offering is part of an effective shelf registration statement with the SEC, which allows for streamlined capital raises.
iCAD, Inc. (NASDAQ: ICAD) announced plans for a public offering of its common stock. The shares will be sold by the company, with an option for underwriters to purchase an additional 15% of the offering. Proceeds will be utilized for working capital and general corporate purposes. The offering is subject to market conditions, with no guarantee of completion or specific terms. Guggenheim Securities is the sole book-running manager. The securities will be offered under an existing effective shelf registration statement with the SEC, emphasizing full compliance with regulatory requirements.